SLXN · Silexion Therapeutics Corp

United States · RS rating 2 · As of 2026-11-03

Price0.15 USD
1-day change+3.6%
RS rating (overall / 1M / 3M / 12M)2 / 6 / 2 / 2
StageDeclining
Composite / Minervini / CANSLIM score24 / 3 / 45
Industry group (rank)Medical-Biomed/Biotech (154)
EPS growth Q/Q+39.2%
Sales growth Q/Q–
Distance from 52-week high+99.5%
Market cap (USD)$3.7M
Open United States in the interactive screener